AIM: To investigate the expression and prognostic value of carbonic anhydrase Ⅱ (CA Ⅱ) and Ki-67 in gastrointestinal stromal tumors (GISTs). METHODS: One hundred and thirteen GIST patients admitted to Chinese People...AIM: To investigate the expression and prognostic value of carbonic anhydrase Ⅱ (CA Ⅱ) and Ki-67 in gastrointestinal stromal tumors (GISTs). METHODS: One hundred and thirteen GIST patients admitted to Chinese People's Liberation Army General Hospital from January 2004 to December 2010 were retrospectively followed up, and immunohistochemistry was used to detect CA Ⅱ, Ki-67 and CD117 expression in tumor samples. The survival rates of the patients were analyzed using the Kaplan-Meier method. Log-rank test, χ 2 test and Cox proportional hazards model were used to determine the relationships between CA Ⅱ, Ki-67 and CD117 expression and prognostic value in GISTs. RESULTS: The survival rates at 1, 3 and 5 years were 90.0%, 82.0% and 72.0% in all patients. However, in patients with positive CA Ⅱ or Ki-67, the survival rates were 92.0%, 83.0% and 77.0% or 83.0%, 66.6% and 53.0%, respectively. Compared with the negative groups, the survival rates in the positive groups were significantly lower (CA Ⅱ log-rankP = 0.000; Ki-67 logrank P = 0.004). Multivariate Cox analysis revealed that CA Ⅱ, CD117 and Ki-67 were considerable immune factors in prognosis of GIST patients (CA Ⅱ P = 0.043; CD117 P = 0.042; Ki-67 P = 0.007). Besides, tumor diameter, mitotic rate, tumor site, depth of invasion, complete resection, intraoperative rupture, and adjuvant therapy were important prognosis predictive factors. Our study indicated that CA Ⅱ had strong expression in GISTs and the prognosis of GISTs with high CA Ⅱ expression was better than that of GISTs with low or no expression, suggesting that CA Ⅱ is both a diagnostic and prognostic biomarker for GIST. CONCLUSION: CA Ⅱ and Ki-67 are significant prognostic factors for GISTs. CA Ⅱ associated with neovascular endothelia could serve as a potential target for cancer therapy.展开更多
Background: Evaluating the tumor proliferative index helps predict clinical behavior and provides prognostic insights for cutaneous basal cell carcinoma (cBCC) and squamous cell carcinoma (cSCC). Objective: This study...Background: Evaluating the tumor proliferative index helps predict clinical behavior and provides prognostic insights for cutaneous basal cell carcinoma (cBCC) and squamous cell carcinoma (cSCC). Objective: This study aimed to identify differences in the proliferative indices among variants of cBCC and cSCC diagnosed at a tertiary healthcare center. Method: Skin biopsies histologically diagnosed as cBCC and cSCC between 2012 and 2018 at the Federal Medical Centre (FMC) Umuahia, Abia State, Nigeria, were analyzed. Archival formalin-fixed, paraffin-embedded (FFPE) tissue blocks were retrieved along with clinical data, and were prepared on charged microscope slides and the immunohistochemical staining was carried out. The primary antibody used in this study was clone BioCare CRM325C (RM) and adenotonsillar tissue blocks/slides served as positive controls. Ki-67 immunohistochemistry was performed on fresh 4µm sections of the tumor specimens. Results: The application of Ki-67 immunoperoxidase on both BCC and SCC cohort, yielded an intense observable brownish nuclear stain in areas of dense proliferating tumour cells on both cutaneous tumours. The average Ki-67 index for all cSCC cases was 24.7%, with a range of 2.3% - 80%, while the mean for cBCC was 15.8%, ranging from 1.2% - 45.6%. Variants with high proliferative indices were observed in 11.9% of cBCC cases and 29.1% of cSCC cases. Among the low proliferative index category, cSCC accounted for 5.4%, while cBCC represented 14.3%. For mild proliferative indices, cSCC cases made up 7.3% and cBCC, 11.9%. The majority of cases showed moderate proliferative indices, with 61.9% for cBCC and 58.2% for cSCC. Overall, there was a significant difference in proliferative indices between cSCC, cBCC, and their variants. Conclusion: The study found a significantly higher rate of cell proliferation, measured by Ki-67 immunostaining, in cSCC and its variants compared to cBCC. However, certain variants of cBCC also exhibited high Ki-67 expression, indicating they can be as aggressive as some cSCC variants.展开更多
目的探讨ADC直方图参数在卵巢癌术前分期评估中的诊断价值,以及与Ki-67表达之间的相关性。方法回顾性分析65例经手术病理证实为原发性卵巢癌患者术前的MRI影像及临床资料(年龄、FIGO分期、Ki-67表达)。使用MaZda软件分析计算出ADC直方...目的探讨ADC直方图参数在卵巢癌术前分期评估中的诊断价值,以及与Ki-67表达之间的相关性。方法回顾性分析65例经手术病理证实为原发性卵巢癌患者术前的MRI影像及临床资料(年龄、FIGO分期、Ki-67表达)。使用MaZda软件分析计算出ADC直方图参数,比较FIGOⅠ~Ⅳ期间各参数的差异。依据相关文献分类方法将Ⅰ期卵巢癌归为早期癌,Ⅱ~Ⅳ期卵巢癌归为晚期癌,采用ROC曲线评估ADC直方图参数对早期卵巢癌的预测效能。探讨ADC直方图参数与Ki-67表达之间的相关性。结果ADC直方图参数值随着卵巢癌分期的增加而降低,Ⅰ期卵巢癌的均值、第1百分位数、第10百分位数显著高于Ⅱ~Ⅳ期(P<0.05),但Ⅱ、Ⅲ、Ⅳ期间无显著差异(P>0.05)。均值、第1百分位数、第10百分位数预测早期卵巢癌的效能良好,其中第1百分位数的AUC最高(0.811),当第1百分位数值≥0.849×10-3 mm 2/s,灵敏性为76.0%,特异性为83.3%。均值、第1百分位数、第10百分位数与Ki-67表达水平呈负相关性。结论ADC直方图参数有助于术前区分早期与晚期卵巢癌,并且与Ki-67表达密切相关。展开更多
p16/Ki-67双重染色检测(双染)作为一种相对客观的检测方法,已在多个国家获批应用于临床。本共识基于循证医学证据,对双染样本的取材与制备、检测流程、结果判读及报告规范达成共识,并推荐双染可用于高危人乳头瘤病毒(high-risk human pa...p16/Ki-67双重染色检测(双染)作为一种相对客观的检测方法,已在多个国家获批应用于临床。本共识基于循证医学证据,对双染样本的取材与制备、检测流程、结果判读及报告规范达成共识,并推荐双染可用于高危人乳头瘤病毒(high-risk human papillomavirus,HR-HPV)初筛不分型阳性或部分分型其他12种(HR 12)阳性人群的分流;也可用于联合筛查时HR-HPV不分型阳性或部分分型HR 12阳性,且细胞学正常或轻度异常时的人群分流;还可用于筛查结果异常(HR-HPV检测或HR-HPV联合细胞学检测)后随访人群的分流。通过本共识的制定,旨在规范双染检测技术的临床应用,实施子宫颈癌精准筛查。展开更多
p16/Ki-67双重染色检测(双染)作为一种相对客观的检测方法,已在多个国家获批应用于临床。本共识基于循证医学证据,对双染样本的取材与制备、检测流程、结果判读及报告规范达成共识,并推荐双染可用于高危人乳头瘤病毒(high-risk human pa...p16/Ki-67双重染色检测(双染)作为一种相对客观的检测方法,已在多个国家获批应用于临床。本共识基于循证医学证据,对双染样本的取材与制备、检测流程、结果判读及报告规范达成共识,并推荐双染可用于高危人乳头瘤病毒(high-risk human papillomavirus,HR-HPV)初筛不分型阳性或部分分型其他12种(HR 12)阳性人群的分流;也可用于联合筛查时HR-HPV不分型阳性或部分分型HR 12阳性,且细胞学正常或轻度异常时的人群分流;还可用于筛查结果异常(HR-HPV检测或HR-HPV联合细胞学检测)后随访人群的分流。通过本共识的制定,旨在规范双染检测技术的临床应用,实施子宫颈癌精准筛查。展开更多
文摘AIM: To investigate the expression and prognostic value of carbonic anhydrase Ⅱ (CA Ⅱ) and Ki-67 in gastrointestinal stromal tumors (GISTs). METHODS: One hundred and thirteen GIST patients admitted to Chinese People's Liberation Army General Hospital from January 2004 to December 2010 were retrospectively followed up, and immunohistochemistry was used to detect CA Ⅱ, Ki-67 and CD117 expression in tumor samples. The survival rates of the patients were analyzed using the Kaplan-Meier method. Log-rank test, χ 2 test and Cox proportional hazards model were used to determine the relationships between CA Ⅱ, Ki-67 and CD117 expression and prognostic value in GISTs. RESULTS: The survival rates at 1, 3 and 5 years were 90.0%, 82.0% and 72.0% in all patients. However, in patients with positive CA Ⅱ or Ki-67, the survival rates were 92.0%, 83.0% and 77.0% or 83.0%, 66.6% and 53.0%, respectively. Compared with the negative groups, the survival rates in the positive groups were significantly lower (CA Ⅱ log-rankP = 0.000; Ki-67 logrank P = 0.004). Multivariate Cox analysis revealed that CA Ⅱ, CD117 and Ki-67 were considerable immune factors in prognosis of GIST patients (CA Ⅱ P = 0.043; CD117 P = 0.042; Ki-67 P = 0.007). Besides, tumor diameter, mitotic rate, tumor site, depth of invasion, complete resection, intraoperative rupture, and adjuvant therapy were important prognosis predictive factors. Our study indicated that CA Ⅱ had strong expression in GISTs and the prognosis of GISTs with high CA Ⅱ expression was better than that of GISTs with low or no expression, suggesting that CA Ⅱ is both a diagnostic and prognostic biomarker for GIST. CONCLUSION: CA Ⅱ and Ki-67 are significant prognostic factors for GISTs. CA Ⅱ associated with neovascular endothelia could serve as a potential target for cancer therapy.
文摘Background: Evaluating the tumor proliferative index helps predict clinical behavior and provides prognostic insights for cutaneous basal cell carcinoma (cBCC) and squamous cell carcinoma (cSCC). Objective: This study aimed to identify differences in the proliferative indices among variants of cBCC and cSCC diagnosed at a tertiary healthcare center. Method: Skin biopsies histologically diagnosed as cBCC and cSCC between 2012 and 2018 at the Federal Medical Centre (FMC) Umuahia, Abia State, Nigeria, were analyzed. Archival formalin-fixed, paraffin-embedded (FFPE) tissue blocks were retrieved along with clinical data, and were prepared on charged microscope slides and the immunohistochemical staining was carried out. The primary antibody used in this study was clone BioCare CRM325C (RM) and adenotonsillar tissue blocks/slides served as positive controls. Ki-67 immunohistochemistry was performed on fresh 4µm sections of the tumor specimens. Results: The application of Ki-67 immunoperoxidase on both BCC and SCC cohort, yielded an intense observable brownish nuclear stain in areas of dense proliferating tumour cells on both cutaneous tumours. The average Ki-67 index for all cSCC cases was 24.7%, with a range of 2.3% - 80%, while the mean for cBCC was 15.8%, ranging from 1.2% - 45.6%. Variants with high proliferative indices were observed in 11.9% of cBCC cases and 29.1% of cSCC cases. Among the low proliferative index category, cSCC accounted for 5.4%, while cBCC represented 14.3%. For mild proliferative indices, cSCC cases made up 7.3% and cBCC, 11.9%. The majority of cases showed moderate proliferative indices, with 61.9% for cBCC and 58.2% for cSCC. Overall, there was a significant difference in proliferative indices between cSCC, cBCC, and their variants. Conclusion: The study found a significantly higher rate of cell proliferation, measured by Ki-67 immunostaining, in cSCC and its variants compared to cBCC. However, certain variants of cBCC also exhibited high Ki-67 expression, indicating they can be as aggressive as some cSCC variants.
文摘目的探讨ADC直方图参数在卵巢癌术前分期评估中的诊断价值,以及与Ki-67表达之间的相关性。方法回顾性分析65例经手术病理证实为原发性卵巢癌患者术前的MRI影像及临床资料(年龄、FIGO分期、Ki-67表达)。使用MaZda软件分析计算出ADC直方图参数,比较FIGOⅠ~Ⅳ期间各参数的差异。依据相关文献分类方法将Ⅰ期卵巢癌归为早期癌,Ⅱ~Ⅳ期卵巢癌归为晚期癌,采用ROC曲线评估ADC直方图参数对早期卵巢癌的预测效能。探讨ADC直方图参数与Ki-67表达之间的相关性。结果ADC直方图参数值随着卵巢癌分期的增加而降低,Ⅰ期卵巢癌的均值、第1百分位数、第10百分位数显著高于Ⅱ~Ⅳ期(P<0.05),但Ⅱ、Ⅲ、Ⅳ期间无显著差异(P>0.05)。均值、第1百分位数、第10百分位数预测早期卵巢癌的效能良好,其中第1百分位数的AUC最高(0.811),当第1百分位数值≥0.849×10-3 mm 2/s,灵敏性为76.0%,特异性为83.3%。均值、第1百分位数、第10百分位数与Ki-67表达水平呈负相关性。结论ADC直方图参数有助于术前区分早期与晚期卵巢癌,并且与Ki-67表达密切相关。
文摘p16/Ki-67双重染色检测(双染)作为一种相对客观的检测方法,已在多个国家获批应用于临床。本共识基于循证医学证据,对双染样本的取材与制备、检测流程、结果判读及报告规范达成共识,并推荐双染可用于高危人乳头瘤病毒(high-risk human papillomavirus,HR-HPV)初筛不分型阳性或部分分型其他12种(HR 12)阳性人群的分流;也可用于联合筛查时HR-HPV不分型阳性或部分分型HR 12阳性,且细胞学正常或轻度异常时的人群分流;还可用于筛查结果异常(HR-HPV检测或HR-HPV联合细胞学检测)后随访人群的分流。通过本共识的制定,旨在规范双染检测技术的临床应用,实施子宫颈癌精准筛查。
文摘p16/Ki-67双重染色检测(双染)作为一种相对客观的检测方法,已在多个国家获批应用于临床。本共识基于循证医学证据,对双染样本的取材与制备、检测流程、结果判读及报告规范达成共识,并推荐双染可用于高危人乳头瘤病毒(high-risk human papillomavirus,HR-HPV)初筛不分型阳性或部分分型其他12种(HR 12)阳性人群的分流;也可用于联合筛查时HR-HPV不分型阳性或部分分型HR 12阳性,且细胞学正常或轻度异常时的人群分流;还可用于筛查结果异常(HR-HPV检测或HR-HPV联合细胞学检测)后随访人群的分流。通过本共识的制定,旨在规范双染检测技术的临床应用,实施子宫颈癌精准筛查。
